Ads
related to: teva pharmaceuticals
Search results
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Zacks via Yahoo Finance· 7 days agoAbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop...
Israel stocks higher at close of trade; TA 35 up 1.42% By Investing.com
Investing.com· 4 days agoIsrael stocks higher at close of trade; TA 35 up 1.42%
100-bagger stocks: These 10 stocks are up more than 100x over the past 20 years
Bankrate via Yahoo Finance· 1 day agoDeckers Outdoor (DECK) Deckers Outdoor designs and sells apparel, footwear and accessories under...
BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages...
Morningstar· 6 days agoNEW YORK, June 15, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to
CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about...
Morningstar· 3 days agoNEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged
UIPATH STOCK NOTICE: Lose Money on Your UiPath, Inc. (NYSE: PATH) Investment When the CEO Resigned?...
Morningstar· 6 days agoNEW YORK, June 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into UiPath, Inc. (NYSE: PATH) for potential violations of the federal securities laws after the CEO resigned and the stock
New Guidance on CGRPs: How/Will it Shape Clinical Practice?
Medscape· 1 day agoNew Guidance on CGRPs as First-Line Migraine Prevention: How/Will it Change Clinical Practice? A...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Zacks· 2 days agoFree Report) announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi ...
Opioids Lawyers Offer Investors Piece of $100 Million-Plus Win
Bloomberg Law· 4 days agoA law firm set to earn more than $100 million for its work on opioids cases is packaging its fees and selling it to investors as a security. Napoli Shkolnik PLLC is pooling its portion of approximately ...
New Standard of Care in High-Risk Acute Promyelocytic Leukemia?
MedPage Today· 4 days agoCombining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly...